Journal of Nuclear Medicine January 2026, jnumed.125.270614; DOI: https://doi.org/10.2967/jnumed.125.270614 ...
Journal of Nuclear Medicine January 2026, jnumed.125.270906; DOI: https://doi.org/10.2967/jnumed.125.270906 ...
You do not have access to the full text of this article, the first page of the PDF of this article appears above. This article requires a subscription to view the full text. If you have a subscription ...
Journal of Nuclear Medicine January 2026, jnumed.125.271074; DOI: https://doi.org/10.2967/jnumed.125.271074 ...
Currently, the most applied 89Zr-immuno-PET platform is the [89Zr]Zr-deferoxamine (DFO)–monoclonal antibody (mAb) constructs, where the investigational agent is obtained through combining ...
The clinical course of glioblastoma is usually rapid and fatal, with a median survival of 1 y. Median survival for anaplastic tumors is 2–3 y. After the initial treatment, these tumors invariably ...
The internal dosimetry schema of the Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine has provided a broad framework for assessment of the absorbed dose to whole ...
The study was designed and performed compliant with Good Clinical Practice, Swiss drug laws, and the Declaration of Helsinki. It was approved by the local ethics committee and registered ...
In malignant tumors, cancer cells are embedded within a complex microenvironment consisting of the extracellular matrix (ECM), blood and lymphatic vessels, infiltrating leukocytes, fibroblasts, and ...
From Compassionate Use Toward High-Level Evidence for Radiopharmaceutical Therapy in Recurrent Meningioma: The LUMEN-1 and MOMENTUM-1 Trials ...
Coregistered MR images and 18F-FDG PET scans of 62-y-old male CADASIL patient (Rankin scale score, 2; MMSE score, 15) illustrate structural and functional relationships. (A) Series of 4 consecutive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results